Amanta Healthcare announces IPO dates. Here are 5 things to know

Amanta Healthcare will launch its IPO on September 1. The book-building issue of 1 crore equity shares is entirely a fresh issue. The subscription window will close on September 3, with allotment expected on September 4 and a tentative listing date on September 8 on the BSE and NSE.

Price Band

The company has not yet announced the price band for its IPO. Investors will be able to place bids in lots, with the lot size details to be updated closer to the opening date.

Issue Structure

The IPO comprises a fresh issue of 1 crore equity shares. Up to 50% of the net issue will be reserved for Qualified Institutional Buyers (QIBs), at least 35% for retail investors, and at least 15% for Non-Institutional Investors (NIIs).

Company Background

Incorporated in 1994, Amanta Healthcare is engaged in the development, manufacturing, and marketing of sterile liquid formulations and medical devices.

Its product portfolio includes IV fluids, diluents, ophthalmic solutions, respiratory care products, irrigation solutions, and eye lubricants. The company uses advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies for packaging.

Amanta markets over 45 generic products through 320 distributors in India and exports to 21 countries across Africa, Latin America, the UK, and other regions.

Financial Performance

For FY25, Amanta Healthcare reported revenue of Rs 276.09 crore, slightly lower than Rs 281.61 crore in FY24. However, profit after tax surged 189% to Rs 10.5 crore in FY25, compared with Rs 3.63 crore in the previous year.

Objects of the IPO

The IPO proceeds will be used for capital expenditure, including Rs 70 crore for setting up a new SteriPort manufacturing line at Hariyala, and Rs 30.13 crore for another new line for SVP at the same location. The balance will be employed for general corporate purposes.

Beeline Capital Advisors is the book-running lead manager, while MUFG Intime India is the registrar to the issue.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)